CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Provided By PR Newswire

Last update: May 2, 2023

SEATTLE, May 2, 2023 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for blood-related cancers, today announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted an equity award to a new employee as an equity inducement award outside of the Company's Amended and Restated 2017 Equity Incentive Plan (but under the terms of the Amended and Restated 2017 Equity Incentive Plan) and material to the employee's acceptance of employment with the company. The equity award was approved on May 1, 2023, in accordance with Nasdaq Listing Rule 5635(c)(4).